Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine

Epilepsia

Volumn 40, Issue 9, 1999, Pages 1198-1209

  Picard, F ^c   Bertrand, S ^b   Steinlein, O K ^a   Bertrand, D ^c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c NONE

Author keywords

ADNFLE; Antiepileptic; Carbamazepine; Nicotinic acetylcholine receptor; Physiology

Indexed keywords

CARBAMAZEPINE; DIZOCILPINE; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT; VALPROIC ACID;

ANIMAL CELL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EPILEPTOGENESIS; FRONTAL LOBE EPILEPSY; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; XENOPUS;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, FRONTAL LOBE; EVOKED POTENTIALS; HUMANS; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; POLYMORPHISM, GENETIC; RECEPTORS, NICOTINIC; VALPROIC ACID; XENOPUS;

EID: 0004529124     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00848.x     Document Type: Article

References (66)

1. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985;27:549-58.
2. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;238:727-38.
3. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:286-94.
4. Sayer RJ, Brown AM, Schwindt PC, Crill WE. Calcium currents in acutely isolated human neocortical neurons. J Neurophysiol 1993; 69:1596-606.
5. Kito M, Maehara M, Watanabe K. Antiepileptic drugs: calcium current interaction in cultured human neuroblastoma cells. Seizure 1994;3:141-9.
6. Granger P, Biton B, Faure C, et al. Modulation of the γ-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol 1995;47:1189-96.
7. Yoshimura R, Yanagihara N, Terao T, Minami K, Abe K, Izumi F. Inhibition by carbamazepine of various ion channels-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol 1995;352:297-303.
8. Hough CJ, Irwin RP, Gao X-M, Rogawski MA, Chuang D-M. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther 1996; 276:143-9.
9. Morselli PL. Carbamazepine: absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:515-28.
10. Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acelylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genet 1995;11:201-3.
11. Steinlein OK, Magnusson A, Stoodt J, et al. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 1997;6:943-7.
12. Weiland S, Witzemann V, Villarroel A, Propping P, Steinlein O. An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett 1996;398:91-6.
13. 2 nicotinic acetylcholine receptors. J Neurosci 1997;17:9035-47.
14. Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant nocturnal frontal lobe epilepsy: a distinctive clinical disorder. Brain 1995;118:61-73.
15. Hayman M, Scheffer IE, Chinvarun Y, Berlangieri SU, Berkovic SF. Autosomal dominant nocturnal frontal lobe epilepsy: demonstration of focal frontal onset and intrafamilial variation. Neurology 1997;49:969-75.
16. Picard F, Rudolf G, Sebastianelli R, et al. A clinical study of 21 European families with dominant partial epilepsy. In: Berkovic S, Genton P, Hirsch E, Picard F, eds. Genetics of focal epilepsies. London: John Libbey, 1999:115-21.
17. Bertrand D, Cooper E, Valera S, Rungger D, Ballivet M. Electrophysiology of neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes following nuclear injection of genes or cDNA. In: Conn M, ed. Methods in neuroscience. New York: Academic Press, 1991:174-93.
18. 2 neuronal nicotinic acetylcholine receptor in HEK-293 cells: a patch-clamp study. J Neurosci 1996;16:7880-91.
19. Faigle JW, Feldmann KF. Carbamazepine: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:499-513.
20. Ogden DC, Siegelbaum SA, Colquhoun D. Block of acetylcholine-activated ion channels by an uncharged local anaesthetic. Nature 1981;289:596-8.
21. Bertrand S, Weiland S, Berkovic SF, Steinlein OK, Bertrand D. Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy. Br J Pharmacol 1998;125:751-60.
22. Buisson B, Curtis L, Bertrand D. Neuronal nicotinic acetylcholine receptor and epilepsy. In: Berkovic S, Genton P, Hirsch E, Picard F, eds. Genetics of focal epilepsies. London: John Libbey, 1999: 187-202.
23. 2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998; 53:555-63.
24. Levy RH, Shen DD. Valproic acid: absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:605-19.
25. + currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 1997;51:1077-83.
26. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 1984;228:523-30.
27. Tomaselli GF, Marban E, Yellen G. Sodium channels from human brain RNA expressed in Xenopus oocytes: basic electrophysiologic characteristics and their modification by diphenylhydantoin. J Clin Invest 1989;83:1724-32.
28. Wakamori M, Kaneda M, Oyama Y, Akaike N. Effects of chlordiazepoxide, chlorpromazine, diazepam, diphenylhydantoin, flunitrazepam and haloperidol on the voltage-dependent sodium current of isolated mammalian brain neurons. Brain Res 1989;494:374-8.
29. Van den Berg RJ, Kok P, Voskuyl RA. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 1993;93: 279-87.
30. + current in neocortical neurons. Epilepsy Res 1998;32:304-8.
31. Vreugdenhil M, van Veelen CW, van Rijen PC, Lopes da Silva FH, Wadman WJ. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 1998;32:309-20.
32. Mutoh K, Dichter MA. Lamotrigine blocks voltage-dependent Na currents in a voltage-dependent manner with a small use-dependent component. Epilepsia 1993;34:87.
33. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36:S2-12.
34. + channels. Mol Pharmacol 1998;54:712-21.
35. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-71.
36. Seino M. A comment on the efficacy of valproate in the treatment of partial seizures. Epilepsia 1994;35:S101-4.
37. Zona C, Tancredi V, Palma E, Pirrone GC, Avoli M. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol 1990; 68:545-7.
38. Olpe H, Kolb CN, Hausdorf A, Haas HL. 4-Aminopyridine and barium chloride attenuate the anti-epileptic effect of carbamazepine in hippocampal slices. Experientia 1991;47:254-7.
39. Lancaster JM, Davies JA. Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice. Experientia 1992;48:751-3.
40. Clark M, Post RM. Carbamazepine, but not caffeine, is highly selective for adenosine A1 binding sites. Eur J Pharmacol 1989; 164:399-401.
41. Okada M, Kiryu K, Kawata Y, et al. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 1997;321:181-8.
42. Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2. Nat Genet 1995;10:117-8.
43. Whiting PJ, Lindstrom JM. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 1988;8:3395-404.
44. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997;53:199-237.
45. Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995;9:6-14.
46. Zoli M, Le Novère N, Hill JAJ, Changeux J-P. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 1995;15:1912-39.
47. Schröder H, Wevers A, Happich E, Schütz U, Moser N. Molecular histochemistry of nicotinic receptors in human brain. In: Becker R, Giacobini E, eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996:269-73.
48. 4 subunit of the nicotinic acetylcholine receptor in the human fetal brain. Brain Res Mol Brain Res 1998; 58:123-31.
49. Rubin MM, Changeux JP. On the nature of allosteric transitions; implications of nonexclusive ligand binding. J Mol Biol 1966;21: 265-74.
50. Leonard RJ, Labarca CG, Charnet P. Davidson N, Lester HA. Evidence that the M2 membrane-spanning region lines the ion channel pore of the nicotinic receptor. Science 1988;242:1578-81.
51. Bertrand D, Changeux JP. Nicotinic receptor: an allosteric protein specialized for intercellular communication. Semin Neurosci 1995; 7:75-90.
52. Arias HR. Luminal and non-luminal non-competitive inhibitor binding sites on the nicotinic acetylcholine receptor [Review]. Mol Membr Biol 1996;13:1-17.
53. Clarke PB, Reuben M, el-Bizri H. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. Br J Pharmacol 1994;111:695-702.
54. Léna C, Changeux J-P, Mulle C. Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci 1993;13:2680-8.
55. Vidal C, Changeux JP. Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 1993;56:23-32.
56. McGehee DS, Heath MJS, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995;269:1692-6.
57. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996;383:713-6.
58. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 1997;68:1511-9.
59. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997;20:92-8.
60. Li X, Rainnie DG, McCarley RW, Greene RW. Presynaptic nicotinic receptors facilitate monoaminergic transmission. J Neurosci 1998;18:1904-12.
61. Oldani A, Zucconi M, Ferini-Strambi L, Bizzozero D, Smirne S. Autosomal dominant nocturnal frontal lobe epilepsy: electroclinical picture. Epilepsia 1996;37:964-76.
62. Curró Dossi R, Paré D, Steriade M. Short-lasting nicotinic and long-lasting muscarinic depolarizing responses of thalamocortical neurons to stimulation of mesopontine cholinergic nuclei. J Neurophysiol 1991;65:393-406.
63. Lavine N, Reuben M, Clarke PBS. A population of nicotinic receptors is associated with thalamocortical afferents in the adult rat: laminal and areal analysis. J Comp Neurol 1997;380:175-90.
64. Lee KH, McCormick DA. Acetylcholine excites GABAergic neurons of the ferret perigeniculate nucleus through nicotinic receptors. J Neurophysiol 1995;73:2123-8.
65. Mesulam M-M. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Prog Brain Res 1996;109:285-97.
66. Danober L, Deransart C, Depaulis A, Vergnes M, Marescaux C. Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog Neurobiol 1998;55:27-57.